Indications for high-dose chemotherapy with autologous stem cell support in patients with systemic amyloid light chain amyloidosis

Transplantation

Volumn 80, Issue SUPPL. 1, 2005, Pages

  Schonland, Stefan O ^a   Perz, Jolanta B ^a   Hundemer, Michael ^a   Hegenbart, Ute ^a   Kristen, Arnt V ^a   Hund, Ernst ^a   Dengler, Thomas J ^a   Beimler, Jorg ^a   Zeier, Martin ^a   Singer, Reinhard ^a   Linke, Reinhold P ^b   Ho, Anthony D ^a   Goldschmidt, Hartmut ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

Author keywords

Amyloid light chain; Autologous stem cell transplantation; High dose melphalan; Treatment related mortality

Indexed keywords

AMYLOID; BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; LENALIDOMIDE; MELPHALAN; PREDNISONE; VINCRISTINE;

AMYLOIDOSIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; HUMAN; LIGHT CHAIN; MORTALITY; MULTIPLE MYELOMA; PLASMA CELL DYSCRASIA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN CONFORMATION; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; AMYLOIDOSIS; CHILD, PRESCHOOL; CLINICAL TRIALS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; MALE; MELPHALAN; MIDDLE AGED; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS;

EID: 27644551331     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000186902.57687.8d     Document Type: Conference Paper

References (23)

1. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004; 351: 1860.
2. Reich G, Held T, Siegert W, et al. Four patients with AL amyloidosis treated with high-dose chemotherapy and autologous stem cell transplantation. Bone Marrow Transplant 2001; 27: 341.
3. Lachmann HJ, Gillmore JD, Pepys MB, et al. Outcome in systemic AL amyloidosis following stem cell transplantation or infusional chemotherapy. Blood 2002; 788.
4. Van Gameren II, Hazenberg BP, Jager PL, et al. AL amyloidosis treated with induction chemotherapy with VAD followed by high dose melphalan and autologous stem cell transplantation. Amyloid 2002; 9: 165.
5. Blum W, Khoury H, Lin HS, et al. Primary amyloidosis patients with significant organ dysfunction tolerate autologous transplantation after conditioning with single-dose total body irradiation alone: a feasibility study. Biol Blood Marrow Transplant 2003; 9: 397.
6. Gertz MA, Lacy MQ, Dispenzieri A, et al. Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate. Bone Marrow Transplant 2004; 34: 1025.
7. Knop S, Lengerke C, Hebart H, et al. High-dose melphalan followed by autologous stem cell transplantation in patients with primary systemic (AL) amyloidosis. Onkologie 2004; 27 (Suppl. 3): 186.
8. Mollee PN, Wechalekar AD, Pereira DL, et al. Autologous stem cell transplantation in primary systemic amyloidosis: the impact of selection criteria on outcome. Bone Marrow Transplant 2004; 33: 271.
9. Perz J, Schonland SO, Hundemer M, et al. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of AL amyloidosis: a single centre prospective phase II study. Br J Haematol 2004; 127: 543.
10. Skinner M, Sanchorawala V, Seldin DC, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004; 140: 85.
11. Moreau P, Leblond V, Baurquelot P. Prognostic factors of survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. Br J Haematol 1998; 101: 766.
12. Gillmore JD, Apperley JF, Craddock C. High dose melphalan and stem cell rescue for AL amyloidosis. In: Kyle, RA, Gertz MA, eds. Amyloid and Amyloidosis. Pearl River, NY: Parthenon Publishing; 1999: 102.
13. Vesole D, Perez WS, Reece DE, et al. High Dose Therapy with Autologous Hematopoietic Stem Cell Transplantation (HSCT) for Patients with Primary Systemic Amyloidosis (AL): Results from the Autologous Blood and Marrow Transplant Registry (ABMTR). Blood 2003; 102: 402.
14. Gertz MA, Blood E, Vesole DH, et al. A multicenter phase 2 trial of stem cell transplantation for immunoglobulin light-chain amyloidosis (E4A97): an Eastern Cooperative Oncology Group Study. Bone Marrow Transplant 2004; 34: 149.
15. Dispenzieri A, Gertz MA, Kyle RA, et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2004; 104: 1881.
16. Gertz MA, Lacy MQ, Dispenzieri A, et al. Stem cell transplantation for the management of primary systemic amyloidosis. Am J Med 2002; 113: 549.
17. Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood 2002; 99: 4276.
18. Sanchorawala V, Wright DG, Seldin DC, et al. High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial. Bone Marrow Transplant 2004; 33: 381.
19. Dispenzieri A, Kyle RA, Lacy MQ, et al. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplant: A case control study. Blood 2004; 103: 3960.
20. Dispenzieri A, Lacy MQ, Kyle RA, et al. Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. J Clin Oncol 2001; 19: 3350.
21. Jaccard A, Moreau P, Leblond V, et al. Best therapy for primary amyloidosis, a not-yet-solved question. Blood 2004; 104: 2990.
22. Bird J. Guidelines in the diagnosis and management of AL amyloidosis. Br J Haematol 2004; 125: 681.
23. Barosi G, Boccadoro M, Cavo M, et al. Italian Society of Hematology; Italian Society of Experimental Hematology, Italian Group for Bone Marrow Transplantation. Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO). Haematologica 2004; 89: 717.